Kurzfassung

BNT411-01 / phase 1/2a, first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BNT411 as a monotherapy in patients with solid tumors and in combination with Atezolizumab, Carboplatin and Etoposide in patients with chemotherapy-naïve extensive-stage small cell lung cancer (ES-SCLC)